MOTS-c
A 16-amino acid peptide encoded within mitochondrial DNA - one of the first mitochondria-derived peptides ever discovered. Regulates glucose metabolism, activates AMPK, and mimics the metabolic effects of exercise at the cellular level. A defining longevity compound of 2026 research.
Reviewed & fact-checked by
Dr. Jane Smith, MD, PhDChief Medical Reviewer · Last updated: March 1, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Makes MOTS-c Unique
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) was discovered in 2015 by researchers at USC. It is one of the first peptides identified as being encoded within mitochondrial DNA -- a discovery that changed our understanding of how mitochondria communicate with the rest of the cell.
Mechanism of Action
- AMPK activation -- MOTS-c activates AMPK through a pathway independent of the AMP/ATP ratio, enabling metabolic adaptation even when cellular energy is not depleted
- Glucose regulation -- translocates to the nucleus under metabolic stress, regulating genes involved in glucose homeostasis and insulin sensitivity
- Exercise mimetic -- animal studies show MOTS-c injection produces metabolic adaptations similar to endurance exercise: increased fatty acid oxidation and improved mitochondrial efficiency
- Anti-inflammatory -- modulates inflammatory cytokine production, reducing chronic low-grade inflammation
The 2026 Research Landscape
MOTS-c is receiving significant research attention for metabolic syndrome, type 2 diabetes, and sarcopenia. Plasma MOTS-c levels naturally decline with age, establishing it as a genuine longevity biomarker.
Stacking Interactions
How MOTS-c interacts with other compounds
Safety Profile — Tier B
Generally safe — moderate evidence
Contraindications
- ●Pregnancy - insufficient safety data
- ●Active cancer - research ongoing
Side Effects
- ●Injection site reactions (subcutaneous)
- ●Mild fatigue in early days (metabolic adaptation)
- ●Long-term safety profile not yet established